KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Liabilities and Shareholders Equity (2016 - 2025)

Exact Sciences (EXAS) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $5.9 billion as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 1.14% to $5.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $23.3 billion, a 9.55% decrease, with the full-year FY2025 number at $5.9 billion, down 1.14% from a year prior.
  • Liabilities and Shareholders Equity was $5.9 billion for Q4 2025 at Exact Sciences, down from $5.9 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $6.7 billion in Q3 2024 to a low of $5.7 billion in Q1 2025.
  • A 5-year average of $6.3 billion and a median of $6.4 billion in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 52.82% in 2021, then dropped 13.13% in 2025.
  • Exact Sciences' Liabilities and Shareholders Equity stood at $6.7 billion in 2021, then decreased by 6.85% to $6.2 billion in 2022, then increased by 3.93% to $6.5 billion in 2023, then fell by 8.39% to $5.9 billion in 2024, then decreased by 1.14% to $5.9 billion in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Liabilities and Shareholders Equity are $5.9 billion (Q4 2025), $5.9 billion (Q3 2025), and $5.8 billion (Q2 2025).